Cargando…

The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa

INTRODUCTION: Parvovirus B19 (PVB19) is one of several viruses transmissible by blood transfusion. Levels of exposure to PVB19 among HIV-infected voluntary blood donors are comparable to those among HIV-negative controls because, in blood donors, the PVB19 infection is transmitted mainly via the res...

Descripción completa

Detalles Bibliográficos
Autores principales: Alain, Chabo Byaene, Antoine, Lufimbo Katawandja, Bizette, Bizeti Nsangu, Dahlia, Pambu, Dophie, Tshibuela Beya, Jérémie, Muwonga Masidi, Donatien, Kayembe Nzongola-Nkasu, Steve, Ahuka Mundeke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255965/
https://www.ncbi.nlm.nih.gov/pubmed/32523647
http://dx.doi.org/10.11604/pamj.2020.35.69.21018
_version_ 1783539818213408768
author Alain, Chabo Byaene
Antoine, Lufimbo Katawandja
Bizette, Bizeti Nsangu
Dahlia, Pambu
Dophie, Tshibuela Beya
Jérémie, Muwonga Masidi
Donatien, Kayembe Nzongola-Nkasu
Steve, Ahuka Mundeke
author_facet Alain, Chabo Byaene
Antoine, Lufimbo Katawandja
Bizette, Bizeti Nsangu
Dahlia, Pambu
Dophie, Tshibuela Beya
Jérémie, Muwonga Masidi
Donatien, Kayembe Nzongola-Nkasu
Steve, Ahuka Mundeke
author_sort Alain, Chabo Byaene
collection PubMed
description INTRODUCTION: Parvovirus B19 (PVB19) is one of several viruses transmissible by blood transfusion. Levels of exposure to PVB19 among HIV-infected voluntary blood donors are comparable to those among HIV-negative controls because, in blood donors, the PVB19 infection is transmitted mainly via the respiratory route. Thus, we hypothesize that the seroprevalence of PVB19 in HIV-positive blood donors is equal to the seroprevalence of PVB19 in HIV-negative blood donors. The objective of this study was to compare the seroprevalence of PVB19 between asymptomatic HIV-positive and HIV-negative blood donors. METHODS: A random sample of 360 eligible blood donors were firstly examined for HIV antibodies by using ELISA automaton and so were categorized as HIV-positive donors and HIV-negative donors. Then the two categories of donors were examined for PVB19 IgG and IgM by using ELISA kits. The seroprevalence of PVB19 in HIV-positive donors was compared to that of HIV-negative donors by using chi-square test or Fisher's exact test. All statistical analyzes were performed with SPSS 21. RESULTS: The prevalences of PVB19 IgG and IgM in HIV-positive blood donors were 92.1% (35 of 38) and 44.7% (17 of 38), respectively and those in control group were 89.1% (287 of 322) and 46.3% (149 of 322), respectively. But for both IgG and IgM the difference was not statistically significant (p > 0.05). CONCLUSION: This research confirms our hypothesis: the seroprevalence of PVB19 in HIV-positive blood donors is equal to the seroprevalence of PVB19 in HIV-negative blood donors.
format Online
Article
Text
id pubmed-7255965
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The African Field Epidemiology Network
record_format MEDLINE/PubMed
spelling pubmed-72559652020-06-09 The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa Alain, Chabo Byaene Antoine, Lufimbo Katawandja Bizette, Bizeti Nsangu Dahlia, Pambu Dophie, Tshibuela Beya Jérémie, Muwonga Masidi Donatien, Kayembe Nzongola-Nkasu Steve, Ahuka Mundeke Pan Afr Med J Research INTRODUCTION: Parvovirus B19 (PVB19) is one of several viruses transmissible by blood transfusion. Levels of exposure to PVB19 among HIV-infected voluntary blood donors are comparable to those among HIV-negative controls because, in blood donors, the PVB19 infection is transmitted mainly via the respiratory route. Thus, we hypothesize that the seroprevalence of PVB19 in HIV-positive blood donors is equal to the seroprevalence of PVB19 in HIV-negative blood donors. The objective of this study was to compare the seroprevalence of PVB19 between asymptomatic HIV-positive and HIV-negative blood donors. METHODS: A random sample of 360 eligible blood donors were firstly examined for HIV antibodies by using ELISA automaton and so were categorized as HIV-positive donors and HIV-negative donors. Then the two categories of donors were examined for PVB19 IgG and IgM by using ELISA kits. The seroprevalence of PVB19 in HIV-positive donors was compared to that of HIV-negative donors by using chi-square test or Fisher's exact test. All statistical analyzes were performed with SPSS 21. RESULTS: The prevalences of PVB19 IgG and IgM in HIV-positive blood donors were 92.1% (35 of 38) and 44.7% (17 of 38), respectively and those in control group were 89.1% (287 of 322) and 46.3% (149 of 322), respectively. But for both IgG and IgM the difference was not statistically significant (p > 0.05). CONCLUSION: This research confirms our hypothesis: the seroprevalence of PVB19 in HIV-positive blood donors is equal to the seroprevalence of PVB19 in HIV-negative blood donors. The African Field Epidemiology Network 2020-03-10 /pmc/articles/PMC7255965/ /pubmed/32523647 http://dx.doi.org/10.11604/pamj.2020.35.69.21018 Text en © Chabo Byaene Alain et al. http://creativecommons.org/licenses/by/2.0/ The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Alain, Chabo Byaene
Antoine, Lufimbo Katawandja
Bizette, Bizeti Nsangu
Dahlia, Pambu
Dophie, Tshibuela Beya
Jérémie, Muwonga Masidi
Donatien, Kayembe Nzongola-Nkasu
Steve, Ahuka Mundeke
The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa
title The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa
title_full The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa
title_fullStr The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa
title_full_unstemmed The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa
title_short The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa
title_sort human parvovirus b19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the blood transfusion national center in kinshasa
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255965/
https://www.ncbi.nlm.nih.gov/pubmed/32523647
http://dx.doi.org/10.11604/pamj.2020.35.69.21018
work_keys_str_mv AT alainchabobyaene thehumanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa
AT antoinelufimbokatawandja thehumanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa
AT bizettebizetinsangu thehumanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa
AT dahliapambu thehumanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa
AT dophietshibuelabeya thehumanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa
AT jeremiemuwongamasidi thehumanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa
AT donatienkayembenzongolankasu thehumanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa
AT steveahukamundeke thehumanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa
AT alainchabobyaene humanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa
AT antoinelufimbokatawandja humanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa
AT bizettebizetinsangu humanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa
AT dahliapambu humanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa
AT dophietshibuelabeya humanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa
AT jeremiemuwongamasidi humanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa
AT donatienkayembenzongolankasu humanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa
AT steveahukamundeke humanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa